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Introduction
The incidence of bladder cancer, which is more often 
observed in men, is increasing in the developed countries. 
The most likely risk factor is smoking (1). Generally, this 
disease classified as three disease states, namely non-muscle-
invasive, muscle-invasive, or metastatic. Non-muscle-
invasive bladder cancer (NMIBC) can involve the mucosa 
(Ta), submucosa, or lamina propria (T1); alternatively, it 
can comprise flat carcinoma in situ (CIS). Moreover, of all 
bladder cancer patients, 70% of patients are diagnosed with 
NMIBC and the rest are diagnosed with muscle-invasive 
(MIBC) or metastatic disease (2). Bladder cancer, comprising 
a heterogeneous epithelial malignancy, most commonly 
presents as exophytic tumors which are confined to the 
mucosa or lamina propria. However, at initial diagnosis, 
25% of patients have MIBC or metastatic disease, which is 
associated with worse prognosis. Accordingly, NMIBC and 
MIBC are both major causes of morbidity and mortality. 
Whereas radical cystectomy comprises the standard care for 
MIBC patients, some of these individuals (clinical stage T2 
unifocal tumor, status-post-complete transurethral bladder 
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tumor resection (TURBT), no hydronephrosis, no CIS, 
and good baseline bladder function) will not be candidates 
for or might decline this treatment, and thus, they might 
be considered for bladder preservation therapy (trimodality 
therapy) with maximum TURBT, followed by combined 
chemoradiation. A multidisciplinary management model is 
resulted from high prevalence of systemic failure of MIBC 
patients. In this context, systemic therapy is important. 
Despite the use of primary surgical management to treat 
MIBC, which is based on radical cystectomy and pelvic 
lymph-node dissection, up to half of patients will obtain 
tumors at distant sites in the end due to the presence of 
pre-existing disseminated occult micrometastases (3,4), 
and for these individuals, perioperative platinum-based 
chemotherapy (PBCT) comprises the standard of care (5). 
Despite such aggressive treatment options, the survival rate 
of advanced or metastatic patients is low; moreover, until 
recently, prognosis is not changed significantly. Thus, it is 
essential to combine local and systemic therapies to improve 
outcomes (6). 
Immunotherapy has been used to treat bladder cancer 
for several decades. So far, Intravesical Bacillus Calmette-
Guérin (BCG) is the best effective intra-vesicle drug for 
NMIBC (7). 
However, there is a limit to the treatment of bladder 
cancer. For disease progression and resistance to PBCT, 
there is only one intermediate treatment option that 
is valid and recently approved by the European Drug 
Administration. However, therapeutic modalities included 
cancer vaccines, immune checkpoint inhibitors (ICPIs) 
and immunogenic therapy are emerging as alternative 
immunotherapy for various bladder cancer patients. Several 
drugs have recently been approved by the Food and Drug 
Administration (FDA) for advanced and metastatic bladder 
cancer as a secondary systemic treatment or primary 
treatment for patients who are unsuitable for PBCT. We 
summarize the current state of immunotherapies and 
advances in the chemotherapy landscape for perioperative 
MIBC treatment. Moreover, we critically review topics 
that require further development, limitations, and future 
perspectives in this field.
Cancer immunology
The immune system has two functions in carcinogenesis, 
specifically, the elimination of cancer cells and facilitating 
the growth and spread of disease via immune evasion (8). 
Based on the theory of immunoediting, the host immune 
system attacks a colony of cancer cells, facilitating their 
elimination. Tumor-specific mutations can result in 
neoantigens that are targeted by the immune system, and 
these differentiate non-self from self (9). CD8+ cytotoxic T 
cells are thought to mediate tumor regression, as they realize 
and specifically target cancer cells which have tumor-specific 
antigens on surface including somatic neoantigens (10). 
Tumor cell recognition by this population is associated 
with exhaustion owing to interactions with inhibitory 
receptor ligands presented by tumor, such as programmed 
death-receptor 1 (PD-1) and programmed death-receptor 
ligand 1 (PD-L1). Moreover, CD8+ cytotoxic T-cell 
activation is accompanied by CD4+ regulatory T cell (Treg) 
accumulation, which results in the suppression of effector 
T cell function (11). These adaptive immune pathways and 
associated factors such as ligands, receptors and mediators 
comprise the primary potential targets of immunotherapy. 
T cell  response frequency and potency, dictating 
immunotherapy efficacy, are particularly modulated by co-
stimulatory and co-inhibitory molecules, and these can be 
further modified by external stimuli (12). Antibody-based 
checkpoint blocks up immunotherapy largely functions 
by upswing the immune system to target tumor cells. 
There is various mechanism, for instance anti-cytotoxic 
T lymphocyte-associated protein-4 (CTLA-4) seems to 
primarily exert its physiologic effects by affecting major 
CD4+ T cell subsets, specifically modulating helper T cell 
(Th) activity, promoting effector T cells and suppressing 
Treg immunosuppressive functions. Immune checkpoint 
factors that are PD-1, PD-L1 and CTLA-4 comprise novel 
targets for immunotherapy, which is based on their co-
inhibitory signals that affect T cell functions with respect to 
normal host cells, which can be imitated by cancer cells (13). 
Overall, tumor antigens cause tumor-specific immune 
reactions in various pathway; moreover, some antigens 
do not inevitably occur tumor rejection. Therefore, 
cancer may vary with regard to sensitivity and response 
to immunotherapy. On the other hand, this is still widely 
used NMIBC treatment modality; further, it has a more 
important role in treatment settings for advanced bladder 
cancer. In addition, there are reports from the “The Cancer 
Genome Atlas” Project (TCGA) indicates that there are 
three subtypes of MIBC based on mutations and deletion 
at regions of DNA amplification (14). Bladder cancer is 
concerned with many different mutations, highlighting 
its potential susceptibility to immunotherapy, based on 
recognizable antigen variability, although the concordance 
between these TGCA-based subtypes and transcriptional 
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subtypes is not currently clear (14).
Neoadjuvant chemotherapy (NACT) in MIBC
Several randomized controlled trials (RCTs) and meta-
analyses have investigated the contribution of NACT, 
administered before radical cystectomy, to improving survival. 
One meta-analysis reported that cisplatin-based combination 
NACT can result in a 16% reduction in overall risk of death, 
compared to that with locoregional therapy alone. When 
considering only regimens comprising cisplatin/carboplatin 
(GC) or methotrexate, vinblastine, doxorubicin, and cisplatin 
(MVAC)-like chemotherapy, NACT is related to even better 
survival [hazard ratio (HR), 0.82; 95% confidence interval 
(CI), 0.74–0.91] with an absolute 5-year survival benefit of 
8% (15). In these studies, PBCT was used, and the results are 
not suitable for supporting non-cisplatin-based therapy in the 
neoadjuvant environment. Some adjuvant studies also showed 
similar efficacy with a gemcitabine-cisplatin combination, 
which is less toxic and has been expanded to a neoadjuvant 
setting (16). 
Thus, in MIBC patients (and particularly those with 
clinical > T3 disease), NACT should be administered if a 
platinum-based regimen can be tolerated by the patient. If 
it cannot be tolerated or in the case of resistance, patients 
should proceed directly to radical cystectomy. Although 
cisplatin-based NACT is associated with pathologic 
downstaging and an overall survival (OS) benefit, more 
than 40% of patients diagnosed with urothelial carcinoma 
remain ineligible for cisplatin-based chemotherapy 
(17,18). Ineligibility is most often secondary to impaired 
renal function but poor performance status, hearing loss, 
peripheral neuropathy, and heart failure are also criteria 
used to exclude cisplatin therapy (18). Even in those patients 
eligible to receive cisplatin, a meta-analysis of 13 trials 
including 886 patients found that the pathologic complete 
response rate for those receiving neoadjuvant cisplatin-
based chemotherapy was only 28.6% (19).
Overall, bladder cancers exhibit a mutational spectrum highly 
enriched in mutations in chromatin regulatory genes (14). 
Differences in mutation patterns suggest that different 
oncogenic mechanisms might be present. Moreover, this 
suggests new targets for bladder cancer treatment. Level 
I evidence suggests PBCT use in the neoadjuvant setting 
(NACT) for MIBC patients prior to radical cystectomy, 
which is associated with improved OS (median survival 76 
vs. 44 months in the intention-to-treat population) and 
optimal results for those exhibiting complete pathological 
response to therapy (20). However, trials investigating 
the use and efficacy of adjuvant PBCT for patients with 
advanced disease have encountered different challenges with 
respect to patient recruitment, design, and the necessity of 
subsequent therapies. Despite this, because effective salvage 
therapies are lacking, many experts suggest that patients 
at a high risk of relapse (pT3/4 and/or pN+) should be 
treated with adjuvant PBCT if neoadjuvant PBCT was not 
previously used. Despite aggressive multimodal therapy 
comprising NACT and radical surgery, many patients with 
MIBC experience disease recurrence and subsequently 
succumb to their disease. Therefore, there is a pressing need 
for alternative or additional treatments for this population. 
In addition to concerns related to potential toxicity, such 
approaches are perceived to offer marginal benefits and it 
has been suggested that additional treatment is not required 
for those with organ-confined disease, resulting in their lack 
of utilization. A recent exploration of urothelial carcinoma 
biomarkers also led to the identification of predictive 
mutations that could help to select patients who are most 
likely to benefit from neoadjuvant therapy.
Immunotherapy in MIBC
As stated, in addition to potential toxicity concerns, these 
neoadjuvant therapies are not used due to their perceived 
relatively low benefit and concerns that additional treatment 
is not required for patients with organ-confined disease. 
Therefore, alternative or additional treatments are needed 
for these individuals. Currently, several immunotherapeutic 
drugs that inhibit immune checkpoints such as PD-1 
(nivolumab/pembrolizumab), PD-L1 (durvalumab/
avelumab), and CTLA-4 (ipilimumab/tremelimumab) have 
been tested and/or are used clinically for various types of 
cancer including urothelial carcinoma. Among these, five 
(atezolizumab, pembrolizumab, nivolumab, durvalumab, 
and avelumab) agents have been approved by the US 
Food and Drug Administration (USFDA); efforts are also 
being made to investigate the efficacy of immunotherapy, 
especially with checkpoint inhibitors (CPIs) for MIBC. 
Whereas results are not available with respect to the 
efficacy of CPIs for patients with MIBC based on the use of 
neoadjuvant or adjuvant therapy, currently, different active 
trials are recruiting patients and are ongoing (Table 1). 
Immunotherapy in the neoadjuvant setting
In the ABACUS phase II trial (NCT02662309), patients 
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Drug(s) investigated Disease state Phase Primary endpoint
Neoadjuvant NCT02662309  
(ABACUS)
Atezolizumab Neoadjuvant in MIBC II Pathological complete  
response
Neoadjuvant NCT02451423 2×3 weekly cycles of  
atezolizumab (one infusion on 
the first day of each cycle) prior 
to cystectomy surgery
Neoadjuvant in MIBC II Pathological complete  
response and immune  
parameters
Neoadjuvant NCT02845323 Nivolumab + urelumab versus 
nivolumab
Neoadjuvant in MIBC with  
cisplatin-ineligible patients
II Immune response of tumor 
infiltrating CD8+ T cell density
Neoadjuvant NCT02812420 Tremelimumab + durvalumab Durvalumab and tremelimumab 
for the treatment of patients with 
muscle-invasive, high-risk  
urothelial cancer that cannot be 
treated with cisplatin-based  
therapy before surgery
I Safety/toxicity
Neoadjuvant NCT02736266 Pembrolizumab MIBC, were scheduled for RC, and 
had a clinical (c) T2–4aN0M0 stage
II Pathological complete  
response
Neoadjuvant NCT02690558 Pembrolizumab + gemcitabine/
cisplatin versus placebo +  
gemcitabine/cisplatin
Neoadjuvant in MIBC II Pathological downstaging to  
< pT2 defined as pT0–T1N0M0 
at the time of cystectomy
Neoadjuvant NCT02365766 Pembrolizumab + gemcitabine/
cisplatin (cisplatin-eligible) or 
gemcitabine (cisplatin-ineligible)
Neoadjuvant in MIBC Ib/II Safety/toxicity
Neoadjuvant NCT02989584 Atezolizumab + gemcitabine/
cisplatin
Metastatic and MIBC I/II Safety/toxicity
Neoadjuvant NCT03549715 ddMVAC + durvalumab (D)  
alone or in combination with 
tremelimumab
Neoadjuvant in MIBC II Pathological complete  
response
MIBC, muscle invasive bladder cancer; ddMVAC, dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin.
with MIBC (T2-T4a) who were candidates for cystectomy 
but considered cisplatin-ineligible received two cycles of 
neoadjuvant atezolizumab. Primary outcomes addressed 
in this study were efficacy, based on pathological complete 
response (pCR), and also safety, relapse-free survival, 
and biomarker analysis. This study achieved its primary 
endpoint with a pCR rate of 31% (27/88; 95% CI: 21–
41%) (21). Moreover, through dual staining for CD8 and 
granzyme B (GZMB), which is an essential effector for 
lymphocyte activity and an alternate marker of activated 
CD8+ cells, these markers were found to be expressed in 
responding tumors associated with an inflamed phenotype 
(14 of 16, 88%); this was in contrast to that in relapsing 
inflamed tumors, which were found to harbor low levels of 
CD8+ and GZMB+ cells (3 of 10, 30%; P<0.05) (21). This 
suggests that preexisting T cell immunity could underlie 
the unexpectedly high response rates in the neoadjuvant 
setting. Further, the immune infiltrate quality, aside from 
CD8 expression, is relevant to the outcome. This reversal 
in biomarker significance suggests that the utility of these 
markers in association with anti-PD-L1 treatment depends 
on the clinical setting of urothelial carcinoma. Moreover, 
TCGA data with gene expression and DNA analysis data 
in this study indicated changes in urothelial carcinoma 
biology with more advanced disease. We thus speculate that 
approaches based on different treatments and biomarkers 
are needed to optimize outcomes in diverse clinical settings. 
The biomarkers identified in those studies, and especially 
those based on post-treatment tissue, could aid in patient 
selection and provide an improved understanding of disease 
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biology.
A  phase  I I  t r i a l  o f  neoad juvant  a tezo l i zumab 
administration based on 1,200 mg for one, two, and three 
doses before cystectomy will give significant information 
regarding the effects of and requirement for multiple CPI 
applications (NCT02451423). In this multi-dose portion 
trial, patients with adverse pathology (pT3/pT4 or N+) at 
the time of cystectomy and no metastatic disease will be 
permitted to receive adjuvant atezolizumab for up to 16 
cumulative doses. For NACT-ineligible patients, but fit to 
undergo surgical resection of their cancer by cystectomy, 
a combination phase II trial is underway comprising two 
nivolumab cycles, an antibody targeting PD-1 to reactivate 
T cells, plus urelumab, an CD137-agonistic antibody with 
additional activating properties, will be compared to two 
cycles of nivolumab alone (NCT02845323). In addition, a 
pilot presurgical study will evaluate durvalumab (a PD-L1 
inhibitor) and tremelimumab (a CTLA-4 inhibitor) safety; 
for this, 28 patients are enrolled. This will determine if 
this is an effective and safe neoadjuvant therapy for MIBC 
patients who are not eligible for cisplatin-based therapy 
(NCT02812420) (22). 
Pembrolizumab before cystectomy was also investigated 
in the PURE01 study (NCT02736266), with the selected 
patients exhibiting predominant variant histologies (usually 
defined by >50% of this component within the tumor 
specimen) (23). In this trial, 21 patients achieved pCR (42%, 
95% CI, 28–57%) and 27 patients experienced pathologic 
downstaging to < pT2 (54%, 95% CI, 39–68%) (23). The 
significant differences in tumor responses, which appeared 
to be mainly dependent on tumor biomarkers instead of 
histological features, suggest that revised inclusion criteria 
should consider squamous-cell carcinoma histologies 
and all patients with rare biological features that lead to 
outstanding responses.
Another phase II trial investigated a combination 
comprising four cycles of pembrolizumab with four cycles of 
gemcitabine/cisplatin prior to cystectomy (NCT02690558); 
this will address the pressing question of the additive 
benefit of immunotherapy in addition to PBCT (23). 
Pembrolizumab response was found to be dependent on 
tumor PD-L1 status. Moreover, the primary pT0 endpoint 
was realized for 54.3% of patients harboring PD-L1-
positive tumors, which was defined based on a combined 
positive score (CPS) comprising PD-L1 expression on 
both immune and tumor cells (CPS ≥10 in 35 patients); 
however, the authors only observed a pCR in 13.3% of 
patients with CPS <10 (n=15). Moreover, tumor mutational 
burden scores of ≥15 mutations/Mb in pretreatment tumors 
were associated with high pT0 frequencies (23). Another 
trial (NCT02365766) will address the effect of cisplatin 
combined with pembrolizumab and gemcitabine prior to 
cystectomy and will include cisplatin-eligible and ineligible.
Adjuvant immunotherapy
Several trials are currently investigating the use of ICPIs in 
an adjuvant setting, in which the evidence of PBCT benefit 
is much lower than that in the neoadjuvant setting (5). In 
general, the eligibility criteria for these studies include the 
following: patients who received NACT with at least pT2 
or node-positive disease at cystectomy; cisplatin-ineligible 
patients with at least pT3 or node-positive disease at 
cystectomy; patients who decline adjuvant cisplatin-based 
chemotherapy with at least pT3 or node-positive disease 
at cystectomy. There are also three adjuvant ICPI clinical 
trials currently underway (Table 2), specifically a randomized 
phase III trial of pembrolizumab versus observation 
for patients with locally-advanced bladder cancer post-
cystectomy (NCT03244384). For high-risk MIBC 
patients unqualified cisplatin-based chemotherapy or with 
persistent muscle-invasive disease despite the use of NACT, 
pembrolizumab administered post-cystectomy will improve 
OS and disease-free survival (24).
In another randomized phase III adjuvant study, 700 
patients harboring PD-L1-positive high-risk urothelial 
carcinomas (muscle-invasive urothelial carcinoma of the 
bladder, renal pelvis, ureter after surgical resection without 
prior PBCT) will be recruited and randomized in a 1:1 
manner to receive atezolizumab at 16 doses for 1 year versus 
observation (NCT02450331). In another trial, a randomized 
phase III study will explore adjuvant nivolumab with 640 
patients based on the same setting compared to that in 
the previous trial; however, whereas biomarker analysis 
of cystectomy specimens will obviously be performed, no 
specific biomarker level is required for entry to the study 
(NCT02632409).
Several trials are also available for ineligible patients 
or those who refuse cystectomy. One is a phase II trial 
comprising pembrolizumab combined with gemcitabine 
and hypofractionated radiotherapy (52 Gy in 20 fractions) 
(NCT02621151), whereas the other is a phase II trial of 
pembrolizumab, cisplatinum (weekly for 6 weeks), and 
radiotherapy (64 Gy in 32 fractions) after maximal TUR-
BT (NCT02662062) to address the bladder-sparing 
space. These trials will be informative with respect to 
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Table 2 Adjuvant immunotherapy-related clinical trials on muscle-invasive bladder cancer
Disease 
setting
Clinical trial  
number
Drug(s) investigated Disease state Phase Primary endpoint
Adjuvant NCT02632409 High-risk MIBC after  
surgical resection
Nivolumab versus placebo III DFS
Adjuvant NCT02450331 High-risk MIBC after  
surgical resection
Atezolizumab versus observation III DFS
Adjuvant NCT03244384 High-risk MIBC after  
surgical resection
Pembrolizumab versus observation III OS, DFS
Adjuvant NCT02662062 After maximally resected 
MIBC
Pembrolizumab and cisplatin and  
radiotherapy
II Safety/toxicity
Adjuvant NCT02621151 MIBC with patients who 
are not candidates for or 
decline radical cystectomy
Pembrolizumab and transurethral  
resection of bladder tumor and gemcitabine 
and external beam radiation therapy
II DFS
Adjuvant NCT02891161 MIBC (T2–4N0–2M0) of the 
bladder
Combining durvalumab with RT followed by 
adjuvant durvalumab
Ib/II Safety/toxicity PFS, 
DCR
MIBC, muscle invasive bladder cancer; DFS, disease free survival; RT, radiotherapy; OS, overall survival; PFS, progression-free survival; 
DCR, disease control rate.
the effect of radiation on antigen release, production of 
immune cell infiltrates, and immune activity based on 
blood parameters; in addition, re-TURBT samples will 
be accessible. Further, in a phase Ib study, durvalumab 
combined with 64.8 Gy administered to the bladder will be 
explored for unresectable and cystectomy-ineligible patients 
(NCT02891161). 
Discussion
Perioperative treatment strategies include therapies 
administered immediately before or after surgery. 
Theore t i c a l l y,  chemotherapy  de l i v e ry  p r io r  to 
(neoadjuvant) or after (adjuvant) definitive local therapy 
should be as efficacious with respect to the elimination 
of micrometastases. Further, preliminary surgery could 
result in pathological confirmation of disease extent before 
systemic therapy. Moreover, 6–15% of patients with MIBC 
reportedly achieve pCR with TURBT alone, and these 
patients have exceptional outcomes without chemotherapy 
(3,20). Thus, the use factors related with recurrence 
risk to improve patient selection for treatments, thereby 
preventing overtreatment or undertreatment, represent a 
clear benefit of adjuvant strategies rather than neoadjuvant 
approaches. However, in practice, many MIBC patients 
who select preliminary surgery never receive adjuvant 
chemotherapy. Bladder cancer is primarily a disease 
affecting the elderly, as the median age at diagnosis is 
73 years; accordingly, radical cystectomy results in marked 
morbidity. For example, a retrospective study based on 
1,142 consecutive patients subjected to radical cystectomy 
indicated that 30% experienced grade 2–5 complications 
within 90 days of surgery, which could effectively delay the 
administration of effective adjuvant chemotherapy (25). 
Thus, perioperative therapy timing might be more critical 
for patients with MIBC, and the proportion of MIBC 
patients receiving chemotherapy might be increased based 
on the use of a neoadjuvant, rather than adjuvant, approach. 
However, neoadjuvant cisplatin-based chemotherapies are 
still underutilized for bladder cancer management, even 
based on a current cohort at a high-volume tertiary center. 
It also seems that adjuvant cisplatin-based chemotherapy 
is underutilized, even for patients with a high risk of 
recurrence. The landscape of bladder cancer treatment has 
evolved rapidly with the introduction of ICPIs for patients 
with advanced disease, and clinical trials are underway to 
evaluate a potential role for these drugs in earlier disease 
states including NMIBC and MIBC. ICPIs are associated 
with long-term durable responses and good safety profiles 
based on a number of clinical trials. However, approximately 
70–80% of patients might not respond to such agents. 
Therefore, more research, based on the combination of 
ICPI therapy and other therapeutic modalities like cytotoxic 
chemotherapy or different therapeutic targets, is required 
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to strengthen the effects of immunotherapies. Promising 
preliminary data for immune checkpoint inhibition in the 
neoadjuvant setting will hopefully lead to the expansion 
of perioperative chemotherapy to include those patients 
ineligible for cisplatin-based therapy, in addition to 
leading to better pathologic responses with associated 
improvements in survival outcomes. Currently, additional 
compounds and combinations are being tested based on 
different clinical situations in many clinical trials. However, 
overall response rates can be improved and thus, additional 
efforts must be made to optimize utility, while controlling 
side effects. This will include future research on biomarkers 
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